{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:51:24Z","timestamp":1791571884311,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82571246"],"award-info":[{"award-number":["82571246"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai \u201cRising Stars of Medical Talents\u201d Youth Development Program","award":["SHWSRS(2025)_071"],"award-info":[{"award-number":["SHWSRS(2025)_071"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-05312-8","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:04:17Z","timestamp":1789070657000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unilateral vitreous amyloidosis as the presenting feature of hereditary transthyretin amyloidosis (TTR p.Val50Met): a case report and focused literature review"],"prefix":"10.1186","volume":"26","author":[{"given":"Zixiang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suqin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2544-1254","authenticated-orcid":false,"given":"Tong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"issue":"4","key":"5312_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/13506129.2020.1835263","volume":"27","author":"MD Benson","year":"2020","unstructured":"Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2020: update and recommendations by the international society of amyloidosis (ISA) nomenclature committee. Amyloid. 2020;27(4):217\u201322. https:\/\/doi.org\/10.1080\/13506129.2020.1835263.","journal-title":"Amyloid"},{"issue":"3","key":"5312_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.4161\/pri.2.3.7488","volume":"2","author":"RN Rambaran","year":"2008","unstructured":"Rambaran RN, Serpell LC. Amyloid fibrils: abnormal protein assembly. Prion. 2008;2(3):112\u20137. https:\/\/doi.org\/10.4161\/pri.2.3.7488.","journal-title":"Prion"},{"issue":"1","key":"5312_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbapap.2004.09.023","volume":"1703","author":"P Raghu","year":"2004","unstructured":"Raghu P, Sivakumar B. Interactions amongst plasma retinol-binding protein, transthyretin and their ligands: implications in vitamin A homeostasis and transthyretin amyloidosis. Biochim et Biophys Acta (BBA) - Proteins Proteom. 2004;1703(1):1\u20139. https:\/\/doi.org\/10.1016\/j.bbapap.2004.09.023.","journal-title":"Biochim et Biophys Acta (BBA) - Proteins Proteom"},{"issue":"19","key":"5312_CR4","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1007\/s00018-009-0109-0","volume":"66","author":"JN Buxbaum","year":"2009","unstructured":"Buxbaum JN, Reixach N. Transthyretin: the servant of many masters. Cell Mol Life Sci. 2009;66(19):3095\u2013101. https:\/\/doi.org\/10.1007\/s00018-009-0109-0.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"5312_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8(1):31. https:\/\/doi.org\/10.1186\/1750-1172-8-31.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"5312_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","volume":"15","author":"D Adams","year":"2019","unstructured":"Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15(7):387\u2013404. https:\/\/doi.org\/10.1038\/s41582-019-0210-4.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"5312_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/13506120802193720","volume":"15","author":"U Hellman","year":"2008","unstructured":"Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pelli\u00c9 C, Plant\u00e9-Bordeneuve V. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid. 2008;15(3):181\u20136. https:\/\/doi.org\/10.1080\/13506120802193720.","journal-title":"Amyloid"},{"issue":"2","key":"5312_CR8","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1001\/archophthalmol.2009.390","volume":"128","author":"R Hara","year":"2010","unstructured":"Hara R. Impact of Liver Transplantation on Transthyretin-Related Ocular Amyloidosis in Japanese Patients. Arch Ophthalmol. 2010;128(2):206. https:\/\/doi.org\/10.1001\/archophthalmol.2009.390.","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"5312_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3109\/13506120209114101","volume":"9","author":"K Haraoka","year":"2002","unstructured":"Haraoka K, Ando Y, Ando E, et al. Presence of variant transthyretin in aqueous humor of a patient with familial amyloidotic polyneuropathy after liver transplantation. Amyloid. 2002;9(4):247\u201351. https:\/\/doi.org\/10.3109\/13506120209114101.","journal-title":"Amyloid"},{"issue":"7","key":"5312_CR10","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/genes12070955","volume":"12","author":"AM Minnella","year":"2021","unstructured":"Minnella AM, Rissotto R, Antoniazzi E, et al. Ocular involvement in hereditary amyloidosis. Genes. 2021;12(7):955\u201380. https:\/\/doi.org\/10.3390\/genes12070955.","journal-title":"Genes"},{"issue":"2","key":"5312_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3109\/13506129.2015.1015678","volume":"22","author":"JM Beir\u00e3o","year":"2015","unstructured":"Beir\u00e3o JM, Malheiro J, Lemos C, Beir\u00e3o I, Costa P, Torres P. Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases. Amyloid. 2015;22(2):117\u201322. https:\/\/doi.org\/10.3109\/13506129.2015.1015678.","journal-title":"Amyloid"},{"key":"5312_CR12","doi-asserted-by":"publisher","first-page":"797223","DOI":"10.3389\/fmed.2021.797223","volume":"8","author":"Q Xu","year":"2022","unstructured":"Xu Q, Wang X, Zhang Z, et al. Case report: vitreous amyloidosis caused by a TTR Lys55Asn mutation with intraoperative suprachoroidal hemorrhage. Front Med. 2022;8:797223. https:\/\/doi.org\/10.3389\/fmed.2021.797223.","journal-title":"Front Med"},{"issue":"1","key":"5312_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000360790","volume":"5","author":"M Seca","year":"2014","unstructured":"Seca M, Ferreira N, Coelho T. Vitreous amyloidosis as the presenting symptom of familial amyloid polyneuropathy TTR Val30Met in a portuguese patient. Case Rep Ophthalmol. 2014;5(1):92\u20137. https:\/\/doi.org\/10.1159\/000360790.","journal-title":"Case Rep Ophthalmol"},{"issue":"4","key":"5312_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/13506120400015580","volume":"11","author":"T Kawaji","year":"2004","unstructured":"Kawaji T, Ando Y, Ando E, Nakamura M, Hirata A, Tanihara H. A case of vitreous amyloidosis without systemic symptoms in familial amyloidotic polyneuropathy. Amyloid. 2004;11(4):257\u20139. https:\/\/doi.org\/10.1080\/13506120400015580.","journal-title":"Amyloid"},{"issue":"12","key":"5312_CR15","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","volume":"10","author":"V Plant\u00e9-Bordeneuve","year":"2011","unstructured":"Plant\u00e9-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10(12):1086\u201397. https:\/\/doi.org\/10.1016\/S1474-4422(11)70246-0.","journal-title":"Lancet Neurol"},{"issue":"1","key":"5312_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1716153.","journal-title":"N Engl J Med"},{"issue":"24","key":"5312_CR17","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","volume":"310","author":"JL Berk","year":"2013","unstructured":"Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658. https:\/\/doi.org\/10.1001\/jama.2013.283815.","journal-title":"JAMA"},{"issue":"8","key":"5312_CR18","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, Martins Da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785\u201392. https:\/\/doi.org\/10.1212\/WNL.0b013e3182661eb1.","journal-title":"Neurology"},{"issue":"5","key":"5312_CR19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.survophthal.2013.12.001","volume":"59","author":"MS Sagoo","year":"2014","unstructured":"Sagoo MS, Mehta H, Swampillai AJ, et al. Primary intraocular lymphoma. Surv Ophthalmol. 2014;59(5):503\u201316. https:\/\/doi.org\/10.1016\/j.survophthal.2013.12.001.","journal-title":"Surv Ophthalmol"},{"key":"5312_CR20","doi-asserted-by":"publisher","first-page":"972501","DOI":"10.3389\/fgene.2022.972501","volume":"13","author":"J Shen","year":"2022","unstructured":"Shen J, Yu H, Lin J, Zhang L, Pan X, Chen Z. Case Report: Hereditary transthyretin (ATTRv) amyloidosis: The p.G103R mutation of the transthyretin gene in a Han Chinese family is associated with vitreous hemorrhage. Front Genet. 2022;13:972501. https:\/\/doi.org\/10.3389\/fgene.2022.972501.","journal-title":"Front Genet"},{"issue":"3","key":"5312_CR21","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/13816810.2022.2025606","volume":"43","author":"AB Trevi\u00f1o-Herrera","year":"2022","unstructured":"Trevi\u00f1o-Herrera AB, Bustamante-Vargas AP, Lisker-Cervantes A, et al. Vitreous involvement as initial presentation of hereditary transthyretin amyloidosis related to the rare TTR Ile107Met (p.Ile127Met) pathogenic variant. Ophthalmic Genet. 2022;43(3):413\u20139. https:\/\/doi.org\/10.1080\/13816810.2022.2025606.","journal-title":"Ophthalmic Genet"},{"issue":"1","key":"5312_CR22","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13256-017-1407-z","volume":"11","author":"B Terrier","year":"2017","unstructured":"Terrier B, Colombat M, Beugnet C, et al. Vitreous amyloidosis with autonomic neuropathy of the digestive tract associated with a novel transthyretin p.Gly87Arg variant in a bangladeshi patient: a case report. J Med Case Rep. 2017;11(1):222. https:\/\/doi.org\/10.1186\/s13256-017-1407-z.","journal-title":"J Med Case Rep"},{"issue":"4","key":"5312_CR23","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/sj.eye.6700075","volume":"16","author":"V Pathak-Ray","year":"2002","unstructured":"Pathak-Ray V, Pulpa V, Blyth C. Vitreous amyloidosis and secondary glaucoma\u2014a case report. Eye. 2002;16(4):492\u20134. https:\/\/doi.org\/10.1038\/sj.eye.6700075.","journal-title":"Eye"},{"issue":"6","key":"5312_CR24","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1136\/bjo.2004.057554","volume":"89","author":"HJ Zambarakji","year":"2005","unstructured":"Zambarakji HJ. Vitreous amyloidosis in alanine 71 transthyretin mutation. Br J Ophthalmol. 2005;89(6):773\u20134. https:\/\/doi.org\/10.1136\/bjo.2004.057554.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"5312_CR25","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3390\/genes13050886","volume":"13","author":"X Zhuang","year":"2022","unstructured":"Zhuang X, Sun Z, Gao F, et al. Ocular manifestations in a chinese pedigree of familial amyloidotic polyneuropathy carrying the transthyretin mutation c.401A\u2009>\u2009G (p.Tyr134Cys). Genes. 2022;13(5):886. https:\/\/doi.org\/10.3390\/genes13050886.","journal-title":"Genes"},{"key":"5312_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.gene.2019.04.030","volume":"705","author":"I Yordanova","year":"2019","unstructured":"Yordanova I, Pavlova Z, Kirov A, et al. Monoallelic expression of the TTR gene as a contributor to the age at onset and penetrance of TTR-related amyloidosis. Gene. 2019;705:16\u201321. https:\/\/doi.org\/10.1016\/j.gene.2019.04.030.","journal-title":"Gene"},{"issue":"10","key":"5312_CR27","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.3390\/biomedicines10102394","volume":"10","author":"K Dugo","year":"2022","unstructured":"Dugo K, Bruno F, Sturiale V, Brancato D, Saccone S, Federico C. Hereditary Transthyretin-Related Amyloidosis: Genetic Heterogeneity and Early Personalized Gene Therapy. Biomedicines. 2022;10(10):2394. https:\/\/doi.org\/10.3390\/biomedicines10102394.","journal-title":"Biomedicines"},{"issue":"7","key":"5312_CR28","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00439-017-1810-y","volume":"136","author":"C Federico","year":"2017","unstructured":"Federico C, Dugo K, Bruno F, Longo AM, Grillo A, Saccone S. Somatic mosaicism with reversion to normality of a mutated transthyretin allele related to a familial amyloidotic polyneuropathy. Hum Genet. 2017;136(7):867\u201373. https:\/\/doi.org\/10.1007\/s00439-017-1810-y.","journal-title":"Hum Genet"},{"issue":"1","key":"5312_CR29","doi-asserted-by":"publisher","first-page":"7141","DOI":"10.1038\/s41467-021-27481-4","volume":"12","author":"I Iakovleva","year":"2021","unstructured":"Iakovleva I, Hall M, Oelker M, Sandblad L, Anan I, Sauer-Eriksson AE. Structural basis for transthyretin amyloid formation in vitreous body of the eye. Nat Commun. 2021;12(1):7141. https:\/\/doi.org\/10.1038\/s41467-021-27481-4.","journal-title":"Nat Commun"},{"issue":"1","key":"5312_CR30","doi-asserted-by":"publisher","first-page":"7623","DOI":"10.1038\/s41467-023-43301-3","volume":"14","author":"M Steinebrei","year":"2023","unstructured":"Steinebrei M, Baur J, Pradhan A, et al. Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis. Nat Commun. 2023;14(1):7623. https:\/\/doi.org\/10.1038\/s41467-023-43301-3.","journal-title":"Nat Commun"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-05312-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05312-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05312-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:09:20Z","timestamp":1791569360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-05312-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5312"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-05312-8","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Under the policy of the Ethics Committee of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, individual case reports based on routine clinical care do not require formal ethics committee review; no formal exemption letter was therefore issued for this single-patient report. All investigations and treatments were part of routine clinical care and the patient was managed according to standard practice. The study adhered to the Declaration of Helsinki. Written informed consent to participate was obtained from the patient. A completed CARE Checklist is available.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of clinical details, ophthalmic images, and genetic findings was obtained from the patient. A copy of the consent form is available for review by the Editor of this journal. Reported data were limited to those clinically necessary, and images were de-identified. The combination of age, a rare genotype, and prior malignancy carries a small re-identification risk; such details are retained only where clinically essential. Source data and consent documentation were held on access-controlled institutional systems; only de-identified data and images were used for manuscript preparation, and no identifiable patient data were transferred outside the treating institution.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"635"}}